Tysabri Progressive Multifocal Leukoencephalopathy Attorney: New Jersey Tysabri PML Injury Lawyer

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Legal Inquiry

For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical conditions, treatment options, and preventive care. This broad educational heritage has empowered individuals to make informed decisions about their well-being, often by contextualizing complex biological processes within everyday life. Within this framework, discussions of therapeutic interventions have historically focused on benefits and standard risk disclosures, maintaining a neutral, evidence-informed stance. As this informational landscape evolves, a natural extension emerges when considering the intersection of pharmaceutical treatments and occupational or environmental exposures. Specifically, the administration of biologic therapies—such as those used for chronic autoimmune conditions—introduces a layer of risk that may not be fully appreciated in general health discourse. When a patient receives a medication like Tysabri, the clinical setting involves controlled monitoring, yet the potential for adverse outcomes, including progressive multifocal leukoencephalopathy (PML), shifts the focus from general awareness to specific liability concerns. This pivot is particularly relevant for individuals who, due to their professional roles or residential circumstances in New Jersey, may have been exposed to factors that compound the risk profile. The transition from broad health education to targeted legal inquiry is thus a matter of practical necessity: understanding how a prescribed therapy interacts with one’s unique exposure history requires moving beyond general science into the realm of personal injury assessment.

Understanding Tysabri and Its Link to PML

Tysabri (natalizumab) is a monoclonal antibody indicated for the treatment of multiple sclerosis and Crohn disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic viral infection of the brain caused by the JC virus (JCV). PML typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, the agency's most stringent safety alert, specifically addressing this risk. The clinical presentation of PML is variable and can include progressive neurological deficits such as weakness, gait disturbance, balance disorder, cognitive impairment, memory loss, and visual changes. In the FDA Adverse Event Reporting System (FAERS) database, the most frequently reported adverse events associated with Tysabri include fatigue (19,150 reports), multiple sclerosis relapse (16,691 reports), headache (9,626 reports), gait disturbance (9,422 reports), memory impairment (7,895 reports), asthenia (7,852 reports), balance disorder (5,621 reports), and cognitive disorder (3,478 reports) (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not specifically confirm PML in every case, they reflect the types of neurological symptoms that may be early indicators of PML and underscore the importance of vigilant monitoring.

Diagnosis and Risk Factors for PML

Diagnosis of PML requires a high index of suspicion. A retrospective national cohort study of 456 Italian PML patients observed between 1987 and 2024 described the changing clinical and laboratory characteristics of the disease. The study included patients with either a definite (n=376, 82.4%) or clinico-radiological (n=80, 17.6%) diagnosis, highlighting that PML can be confirmed through a combination of clinical, radiological, and laboratory findings (https://pubmed.ncbi.nlm.nih.gov/40922664/). Typical magnetic resonance imaging (MRI) findings include multifocal, asymmetric white matter lesions without mass effect, and detection of JCV DNA in cerebrospinal fluid is a key diagnostic criterion. The mechanistic pathway linking Tysabri to PML involves its pharmacological action. Tysabri is a humanized monoclonal antibody that binds to alpha-4 integrin, blocking the adhesion of leukocytes to endothelial cells and thereby preventing their migration into the central nervous system (CNS). This reduces inflammatory activity in multiple sclerosis but also impairs immune surveillance within the CNS. Under normal conditions, the immune system controls JCV replication. When Tysabri disrupts this surveillance, JCV can reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the clinical syndrome of PML. Three specific risk factors for PML in Tysabri-treated patients have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk for developing PML. These factors should be considered in the context of expected benefit when initiating and continuing treatment with Tysabri. Healthcare professionals are advised to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Legal Considerations for Tysabri-Related PML in New Jersey

The adequacy of warnings regarding Tysabri and PML is a critical issue. The boxed warning clearly states that Tysabri increases the risk of PML and that the infection usually leads to death or severe disability. The warning also notes that Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which is designed to ensure that patients are informed of the risks and that monitoring occurs (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions may arise about whether prescribers and patients fully understand the magnitude of the risk, the specific risk factors, and the importance of early detection. For patients who develop PML, the timeline between exposure and documented harm can vary. PML may occur months to years after starting Tysabri, with risk increasing with longer treatment duration, especially beyond two years. The latency period complicates the attribution of harm to the drug, particularly if other immunosuppressive therapies were used previously. For affected patients and their families, attorney-related considerations may include evaluating whether the warnings provided were adequate and whether the patient's specific risk factors were properly assessed and communicated. Patients who develop PML after Tysabri therapy may face catastrophic neurological disability, requiring long-term care and rehabilitation. Legal claims may focus on failure to warn, failure to monitor, or failure to discontinue therapy promptly when symptoms emerged. The restricted distribution program does not eliminate the possibility of inadequate risk communication, and each case must be evaluated on its individual facts. In summary, Tysabri is associated with a well-documented risk of PML, a severe and often fatal brain infection. The FDA has mandated a boxed warning and a restricted distribution program to mitigate this risk. However, the clinical presentation of PML can be subtle, and early diagnosis is challenging. Patients with anti-JCV antibodies, longer treatment duration, or prior immunosuppressant use are at highest risk. For those who suffer harm, legal evaluation may be warranted to determine whether the warnings and monitoring were adequate.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Tysabri and how is it linked to PML?

Tysabri (natalizumab) is a monoclonal antibody used to treat multiple sclerosis and Crohn disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. The FDA has issued a boxed warning for this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

What are the symptoms of PML in Tysabri patients?

Symptoms include progressive weakness, gait disturbance, balance disorder, cognitive impairment, memory loss, and visual changes. FAERS data shows frequent reports of fatigue, gait disturbance, memory impairment, and balance disorder (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI).

How is PML diagnosed?

Diagnosis involves MRI showing multifocal white matter lesions and detection of JCV DNA in cerebrospinal fluid. A study of 456 Italian PML patients confirmed diagnosis through clinical, radiological, and laboratory findings (https://pubmed.ncbi.nlm.nih.gov/40922664/).

What are the risk factors for PML with Tysabri?

Three key risk factors: presence of anti-JCV antibodies, treatment duration beyond two years, and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Can I file a lawsuit if I developed PML from Tysabri in New Jersey?

Legal claims may be possible if warnings were inadequate or monitoring was insufficient. Each case is evaluated individually. Consult a New Jersey attorney experienced in pharmaceutical injury to discuss your situation.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.